Used in the treatment of hypercholesterolemia and prevention of cardiovascular diseases by targeting PCSK9, a protein that regulates LDL cholesterol levels in the blood. By inhibiting PCSK9, this antibody increases the number of LDL receptors on liver cells, enhancing clearance of LDL cholesterol and significantly lowering circulating levels. It is administered as a subcutaneous injection and is particularly effective in patients with familial hypercholesterolemia or those who cannot achieve target cholesterol levels with statins alone. Its high specificity and potency make it a valuable therapeutic option in long-term management of atherosclerotic cardiovascular disease.